We know there is significant frustration in the US regarding the cost of healthcare – including prescription medicines. We take this very seriously, as evidenced by our pricing track record. In fact, the launch price of our six most recently introduced new medicines were priced similarly or less than the market leader. This illustrates our commitment to appropriately balance reward for our innovation and ensure broadest patient access.
When it comes to improving the quality and cost of healthcare across the US healthcare system, we know we have a role to play, and we are determined to help find solutions alongside payers, policymakers, physicians, and others.
Behind our pricing efforts are people like Nick, who leads our US pricing team. Using a value-based approach, Nick and his team help determine an appropriate price for new GSK medicines in the US.
"I’m proud to work for the #1 most access-oriented pharmaceutical company in the world, and here in the US we never launch a product without considering affordability for the patients who need it most."
This article is part of a series on our responsible business in the US.